Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings

Brunetti, Natale Daniele; Pellegrino, Pier Luigi; Cuculo, Andrea

doi:10.1016/j.ejim.2006.07.031

Cited by 33 publications

(28 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severity of coronary atherosclerosis has been also related to plasmatic levels of CRP, APPs [2] and other inflammatory cytokines levels [3]. Moreover, the link between endothelial dysfunction and inflammatory activation, expressed by raised concentrations of markers of inflammation, has been clearly reported [4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 98%

“…Acute coronary syndromes (ACSs) are characterized by an inflammatory systemic response which reflects in increased circulating levels of C-reactive protein (CRP) [1] and acute phase proteins (APPs) [2]. Severity of coronary atherosclerosis has been also related to plasmatic levels of CRP, APPs [2] and other inflammatory cytokines levels [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment

Brunetti

Padalino

Cuculo

et al. 2008

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment

Brunetti

Padalino

Cuculo

et al. 2008

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Each of these diseases involves modulating expression of apolipoprotein subfractions, most often due to replacement by acute-phase response proteins like serum amyloid A (SAA) and complement component 3. Increased levels of the acutephase response protease inhibitor ␣-1-antitrypsin (A1AT) are also believed to be involved in the pathogenesis of acute MI (161,162 ). Integration of SAA, complement component 3, and A1AT into HDL particles limits its antiinflammatory functionality and thus may contribute to the pathogenesis of vascular disease (163,164 ).…”

Section: Composition and Role Of Hdl-associated Proteinsmentioning

confidence: 99%

The Changing Face of HDL and the Best Way to Measure It

Karathanasis¹,

Freeman

Gordon

et al. 2017

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND: HDL cholesterol (HDL-C) is a commonly used lipid biomarker for assessing cardiovascular health. While a central focus has been placed on the role of HDL in the reverse cholesterol transport (RCT) process, our appreciation for the other cardioprotective properties of HDL continues to expand with further investigation into the structure and function of HDL and its specific subfractions. The development of novel assays is empowering the research community to assess different aspects of HDL function, which at some point may evolve into new diagnostic tests. CONTENT:This review discusses our current understanding of the formation and maturation of HDL particles via RCT, as well as the newly recognized roles of HDL outside RCT. The antioxidative, antiinflammatory, antiapoptotic, antithrombotic, antiinfective, and vasoprotective effects of HDL are all discussed, as are the related methodologies for assessing these different aspects of HDL function. We elaborate on the importance of protein and lipid composition of HDL in health and disease and highlight potential new diagnostic assays based on these parameters.

show abstract

“…Furthermore, we show a significant association between high Cp and poor long-term prognosis independent of traditional cardiac risk factors. Although elevated Cp is associated with cardiovascular events in other populations of healthy individuals (5-7), the setting of acute coronary syndromes (8,9), and stable cardiac patients (10), this study is the first study, to our knowledge, that examines the relationship between serum Cp and clinical outcomes in patients with CKD. It is conceivable that future studies designed to modulate Cp's cardio-and possibly even renoprotective effects will present novel therapeutic strategies in this population, which suffers from significant cardiovascular morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

“…In vitro, Cp shows NO oxidase activity by catalytic consumption of NO, whereas Cp immunodepletion, Cp knockout mice, and humans with congenital aceruloplasminemia all show diminished plasma NO oxidase activity (4). Several studies have also connected Cp levels with increased cardiovascular risk in both the normal population (5-7) and patients with acute coronary syndromes (8,9). In particular, our group has shown the prognostic value of elevated Cp, even after adjustment for traditional risk factors, for determining the future risk of cardiac events in stable cardiac patients (10).…”

Section: Introductionmentioning

confidence: 99%

Plasma Ceruloplasmin, a Regulator of Nitric Oxide Activity, and Incident Cardiovascular Risk in Patients with CKD

Kennedy

Fan

et al. 2014

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives Increased serum levels of the acute-phase reactant ceruloplasmin predict adverse clinical outcomes in the setting of acute coronary syndromes and heart failure, but their role in patients with CKD is unclear. This study investigated the relationship of ceruloplasmin with clinical outcomes in CKD, especially with regard to traditional cardiac biomarkers.Design, setting, participants, & measurements Serum ceruloplasmin levels in consecutive study participants with CKD (n=654; estimated GFR,60 ml/min per 1.73 m 2 ) as well as a control group of non-CKD participants matched for age and sex (n=250) were measured. Study participants were enrolled during 2001-2006 from a population of patients presenting for elective diagnostic coronary angiography and prospectively followed for 3 years (median follow-up=1095 days) to determine incident major adverse cardiac events (defined as a composite of death, nonfatal myocardial infarction, and stroke).Results Serum ceruloplasmin levels in CKD patients were elevated versus controls (median [interquartile range]; 25.5 [21.8-29.6] versus 22.7 [19.7-26.5] mg/dl; P,0.001) and associated with increased risk of future major adverse cardiac events (hazard ratio, 1.35; 95% confidence interval, 1.0 to 1.82; P=0.04). After adjusting for traditional risk factors, higher serum ceruloplasmin was still associated with higher risk of major adverse cardiac events at 3 years (hazard ratio, 1.61; 95% confidence interval, 1.15 to 2.25; P=0.01). ConclusionIn CKD patients, increased serum ceruloplasmin, a regulator of nitric oxide activity, is associated with increased risk of long-term adverse cardiovascular events, even after multivariable model adjustment for traditional clinical and biologic risk factors.

show abstract

Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings

Cited by 33 publications

References 41 publications

Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment

Acute phase proteins activation in subjects with coronary atherosclerosis and micro-vessel coronary circulation impairment

The Changing Face of HDL and the Best Way to Measure It

Plasma Ceruloplasmin, a Regulator of Nitric Oxide Activity, and Incident Cardiovascular Risk in Patients with CKD

Contact Info

Product

Resources

About